端粒酶在癌症正在进行的探索和未来的发现
Apurwa Mishra1, Trupti N Patel2
1Department of Integrative Biology, School of Bio-Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, India.
端粒酶,包括端粒酶逆转录酶 (TERT) 和端粒酶RNA成分 (TERC),在癌症中至关重要. TERT和TERC的重新激活驱动癌症的进展,并提供治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 端粒酶,包括端粒酶逆转录酶 (TERT) 和端粒酶RNA成分 (TERC),通常在分化的人类细胞中被抑制.
- 端粒酶的失调通过端粒依赖和独立的途径导致癌症,在晚期癌症中活性升高.
- TERT和TERC的作用不仅仅是端粒维护,还影响基因表达,信号传递和新陈代谢.
研究的目的:
- 审查端粒酶在癌症发展和进展中的多方面的作用.
- 探索TERT的非正规功能,包括其核和线粒体的作用.
- 讨论针对癌症治疗中的端粒酶和TERT的治疗策略.
主要方法:
- 关于癌症中的端粒酶,TERT和TERC研究的文献综述.
- 对端粒酶在基因表达,细胞代谢和DNA保护中的作用的分析.
- 探索致癌病毒策略来操纵端粒酶活性.
- 审查当前和新兴的端粒酶向癌症疗法.
- 在端粒研究中考虑计算建模应用.
主要成果:
- 在早期瘤发生过程中观察到TERT的重新激活和TERC的上调.
- 在核和线粒体中TERT的存在突出了非正规的功能,防止细胞死亡和保护线粒体DNA.
- 端粒酶活性与癌细胞中改变的葡萄糖代谢和表观遗传调节有关.
- 致癌病毒利用策略来增强对癌症进展的端粒酶活性.
- 端粒酶抑制剂,营养保健品和疫苗是有前途的治疗途径.
结论:
- 端粒酶,特别是TERT,在癌症发病和进展中起着关键作用.
- 理解端粒酶激活机制对于开发有效的向疗法至关重要.
- 计算建模为端粒研究和治疗开发提供了新的洞察力.
更多相关视频
08:34Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
Published on: April 13, 2015
10:14Telomerase Activity in the Various Regions of Mouse Brain: Non-Radioactive Telomerase Repeat Amplification Protocol TRAP Assay
Published on: September 2, 2014
相关概念视频
Telomeres and Telomerase
Replicative Cell Senescence
Replication in Eukaryotes
Many Proteins Orchestrate Replication at the Origin
Eukaryotic replication follows many of the same...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Targeted Cancer Therapies
There are several types of targeted therapies against...
